QRG Capital Management Inc. Buys 1,309 Shares of Supernus Pharmaceuticals, Inc. $SUPN

QRG Capital Management Inc. grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 7.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,892 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,309 shares during the period. QRG Capital Management Inc.’s holdings in Supernus Pharmaceuticals were worth $595,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter valued at about $41,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter valued at about $46,000. GAMMA Investing LLC boosted its stake in shares of Supernus Pharmaceuticals by 116.7% during the 2nd quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,541 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter valued at about $103,000. Finally, State of Wyoming boosted its stake in shares of Supernus Pharmaceuticals by 58.8% during the 1st quarter. State of Wyoming now owns 4,754 shares of the specialty pharmaceutical company’s stock valued at $156,000 after purchasing an additional 1,761 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $49.51 on Friday. The firm’s 50 day moving average price is $44.69 and its 200-day moving average price is $36.56. The company has a market cap of $2.78 billion, a PE ratio of 43.05 and a beta of 0.78. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $51.78.

Insider Activity

In other news, CFO Timothy C. Dec sold 11,780 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $44.49, for a total transaction of $524,092.20. Following the completion of the transaction, the chief financial officer directly owned 1,246 shares of the company’s stock, valued at $55,434.54. The trade was a 90.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Frank Mottola sold 14,000 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $44.51, for a total transaction of $623,140.00. Following the transaction, the senior vice president directly owned 15,496 shares of the company’s stock, valued at $689,726.96. The trade was a 47.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 302,841 shares of company stock valued at $13,361,449 over the last three months. Corporate insiders own 8.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald lifted their target price on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research note on Tuesday, September 30th. Piper Sandler raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $40.00 to $65.00 in a research note on Thursday. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $64.00.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.